PerkinElmer
Revvity Q2 Revenues Down on COVID Testing Declines; Organic Dx Revenues Rise
The firm reported 8 percent organic growth in diagnostics, excluding COVID-19, but it also saw lower spending on instruments, contracts, and technology deals.
The firm reported Thursday its Q1 revenues declined 30 percent as COVID-19 revenues dwindled but non-COVID organic revenues grew 6 percent.
In Brief This Week: PerkinElmer, CDC, Opko, DermTech, OpGen, More
News items for the week of May 1, 2023.
In Brief This Week: Chembio, Gradientech, PerkinElmer, Becton Dickinson, More
News items for the week of April 24, 2023.
In Brief This Week: PerkinElmer, Roche, T2 Biosystems, Co-Diagnostics, More
News items for the week of March 13, 2023.